ADD ANYTHING HERE OR JUST REMOVE IT…
Wrong menu selected
Acarix Acarix
  • Product

    Background

    • What is Coronary Artery Disease (CAD)?
    • Diagnosing CAD

    About the product

    • The CADScor® System
    • How does it work
  • Resources

    Testimonials

    • HCP stories
    • Patient stories

    References

    • Clinical Studies
    • Questionnaire
    • Downloads (US)
    • Downloads (EU)
    • Education

    Support

    • Training
    • FAQ
    • Reimbursement

    Physician Locator

    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Rights Issue/Warrant Program
    • Previous Rights Issue
    • Investor Presentations
  • Company

    Who we are

    • About Acarix
    • leadership
    • Join the team

    Get in touch

    • Contact us
    • Investigator Initiated Study
  • News
    • Press
    • Events
    • Social Media
Account
Search
Book a Demo
Acarix Acarix
Book a demo
Menu
author-avatar acarix
Press
August 6, 2024
26 Nov 2020

FDA identifies exclusive code for the CADScor®

Press release (MAR)Malmö, Sweden, November 26, 2020 FDA identifies exclusive code for the CADScor® After yesterday’s announcement and...
Continue reading
author-avatar acarix
Press
August 6, 2024
25 Nov 2020

Acarix erhåller marknadsgodkännande för CADScor® System för försäljning på den amerikanska marknaden

Pressmeddelande (MAR) Malmö, Sverige, 25 november 2020 Acarix erhåller marknadsgodkännande för CADScor®  System för försäljning på den...
Continue reading
author-avatar acarix
Press
August 6, 2024
25 Nov 2020

Acarix receives US market approval for the CADScor® System

Press release (MAR)Malmö, Sweden November 25, 2020 Acarix receives US market approval for the CADScor® System Acarix AB (publ) today...
Continue reading
author-avatar acarix
Press
August 6, 2024
12 Nov 2020

Rättelse: Delårsrapport 2020-01-01 till 2020-09-30

Press release (MAR) Malmö, 12 november, 2020 Rättelse: Delårsrapport 2020-01-01 till 2020-09-30 I den delårsrapport som Acarix lä...
Continue reading
author-avatar acarix
Press
August 6, 2024
12 Nov 2020

Correction: Interim report 2020-01-01 to 2020-09-30

Press release (MAR) Malmö, November 12, 2020 Correction: Interim report 2020-01-01 to 2020-09-30 In the interim report that Acarix ...
Continue reading
author-avatar acarix
Press
August 6, 2024
12 Nov 2020

A Successful Rights Issue with Focus on Sales!

Press release (MAR) Malmö, November 12, 2020 Acarix AB (publ) publishes Interim Report, January – September 2020 A Successful Rights ...
Continue reading
author-avatar acarix
Press
August 6, 2024
12 Nov 2020

En framgångsrik emission med fokus på försäljning!

Press release (MAR) Malmö, 12 november, 2020 Acarix AB (publ) publicerar delårsrapport, januari – september 2020 En framgån...
Continue reading
author-avatar acarix
Press
August 6, 2024
29 Sep 2020

Acarix carries out a directed issue of shares to guarantors in conjunction with the oversubscribed rights issue

Press release Malmö, Sweden September 29, 2020 Acarix carries out a directed issue of shares to guarantors in conjunction with the ove...
Continue reading
author-avatar acarix
Press
August 6, 2024
29 Sep 2020

Acarix genomför riktad nyemission av aktier till garanter i samband med den övertecknade företrädesemissionen

Pressmeddelande Malmö, Sverige, 29 september 2020 Acarix genomför riktad nyemission av aktier till garanter i samband med den överteck...
Continue reading
author-avatar acarix
Press
August 6, 2024
28 Sep 2020

Sista dag för handel med BTA

Pressmeddelande Malmö, Sverige, 28 september 2020 Sista dag för handel med BTA Sista dag för handel med Acarix AB:s (”Acarix” eller ”...
Continue reading
author-avatar acarix
Press
August 6, 2024
28 Sep 2020

Last day of trading in paid subscribed shares (Sw. BTA)

Press release Malmö, Sweden September 28, 2020 Last day of trading in paid subscribed shares (Sw. BTA) Last day of trading in subscri...
Continue reading
author-avatar acarix
Press
August 6, 2024
11 Sep 2020

Acarix announce final outcome in oversubscribed rights issue

Press release Malmö, Sweden September 11, 2020 Acarix announce final outcome in oversubscribed rights issue Acarix AB ("Acarix&...
Continue reading
  • «
  • ‹
  • 10
  • 11
  • 12
  • 13
  • 14
  • ›
  • »
Acarix AB
Jungmansgatan 12
211 19 Malmö
SE
[email protected]

Product

Background

  • What is Coronary Artery Disease (CAD)?
  • Diagnosing CAD

About the product

  • The CADScor® System
  • How does it work

Resources

Testimonials

  • HCP stories
  • Patient stories

Support

  • Training
  • FAQ

References

  • Clinical Studies
  • Downloads (US)
  • Downloads (EU)

Investors

  • Corporate Governance
  • General Meetings
  • Financial Reports and Calendar
  • The Acarix Share
  • Rights Issue
  • Investor Presentations

Company

Who we are

  • About Acarix
  • Management
  • Join the team

Get in touch

  • Contact us
  • LinkedIn
  • Twitter

News

  • Press
  • Events
  • Cookie policy
  • Privacy Policy: Clinical Studies
  • Privacy Policy
  • Cookie policy
  • Privacy Policy: Clinical Studies
  • Privacy Policy

Acarix, 2025. All rights reserved V5

  • Products
    • Background
    • What is Coronary Artery Disease
    • Diagnosing CAD
    • About the product
    • The Cadscor System
    • How Does it Work
  • Resources
    • Testimonial
    • HCP Stories
    • Patients Stories
    • References
    • Clinical Studies
    • Downloads (US)
    • Downloads (EU)
    • Support
    • Training
    • Faq
    • Reimbursement
    • Physician Locator
    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Right Issue
    • Previous Rights Issue
    • Investor Presentations
  • Company
    • Who we are
    • About Acarix
    • Leadership
    • Join The Team
    • Get in touch
    • Contact Us
    • Investigator Initiated Study
  • News
    • News
    • Press
    • Events
    • Socialmedia
Start typing to see products you are looking for.